Rhythm Pharmaceuticals, Inc. (RYTM) Earnings Call Transcripts
Rhythm Pharmaceuticals, Inc.'s Latest Earnings Call - June 13, 2026
Rhythm Pharmaceuticals reported positive interim data from its Phase II trial of setmelanotide in patients with Prader-Willi syndrome (PWS) during the earnings call held on June 13, 2026. The trial demonstrated a mean BMI decrease of 3.06% across 17 patients, with significant improvements in hyperphagia and anxiety scores. Management expressed confidence in advancing to Phase III trials, indicating a strong belief in the drug's efficacy and the potential for regulatory approval. No specific revenue or earnings figures were disclosed, but the positive trial results could drive stock movement as investors assess the implications for future commercialization.
Reported metrics
| Metric | Value |
|---|---|
| Mean BMI Decrease | 3.06% (positive) |
| Mean Fat Mass Reduction | 4.19% (positive) |
| Patient Retention Rate | 100% (positive) |
| Mean HQ-CT Score Change | 7 points or greater decrease in 8 of 10 patients (positive) |
| Mean PADQ Score Change | 11 points or greater decrease in 6 of 8 patients (positive) |
| Dosing Range | 4 to 4.5 mg (positive) |
Guidance from management
Management signaled confidence in moving to Phase III trials, emphasizing the potential for significant clinical benefits and regulatory approval based on the data collected thus far.
What management said
I want to acknowledge all the work you do for the Prader-Willi community. You have participated in most of the clinical trials which have been run in this population. And as we at Rhythm have come to appreciate, these are very challenging trials to conduct.
Most patients seem to have a relatively consistent response to treatment across the different outcome measures with the exception of patients 1 and 5. And I know we discussed these patients on the December call, but can you remind us a little bit of sort of who they are and what was challenging about these patients?
What analysts pressed on
Analysts expressed concerns about the severity of the patient population and the potential for variability in treatment outcomes. There were questions regarding the long-term efficacy and the regulatory pathway for approval, particularly in a rare disease setting.
Main topics on the call
- Positive Phase II Trial Results — The Phase II trial showed a mean BMI decrease of 3.06% and a 4.19% reduction in fat mass while preserving lean mass. Management stated, "everything is moving in the same direction" across multiple measures, reinforcing c...
- Patient Retention and Satisfaction — All 17 patients remained in the trial, with management noting that patients and their families reported increased happiness and improved behavior. Dr. Miller highlighted, "Everyone is really thrilled" with the treatment ...
- Challenges in Patient Population — The trial included a particularly challenging patient population, with severe obesity and uncontrolled diabetes. Dr. Miller noted, "these were the worst of the worst patients for me," indicating the complexity of the cas...
- Future Development Plans — Management confirmed plans to proceed with Phase III trials, focusing on both hyperphagia and BMI outcomes. They stated, "we can imagine running 2 trials," which indicates a strategic approach to addressing different asp...
Read the full Rhythm Pharmaceuticals, Inc. transcript (June 13, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. (RYTM) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 65 calls on record spanning May 12, 2020 to August 4, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 65 Rhythm Pharmaceuticals, Inc. earnings call transcripts on record, spanning May 12, 2020 to August 4, 2026. Based on this history, Rhythm Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated August 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- RYTM
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 65
- First call
- May 12, 2020
- Most recent
- August 4, 2026
- Reporting cadence
- quarterly